RJ Hamster
Get daily coverage of the latest news and important stories in politics, culture, education, and sports at dailywire.com.
— Read on www.dailywire.com/watch
RJ Hamster
RJ Hamster
Economy
Editorial Team
March 04, 2026
4 min read
Spain’s Prime Minister has delivered a sharp rebuke to President Trump’s latest trade threat, declaring “no to war” after the U.S. president pledged to sever trade relations with Madrid over Spain’s position on the Iran conflict. The dispute centers on Spain’s stance regarding U.S. military base access related to Iran operations, and the situation represents another front in the increasingly complex geopolitical landscape facing investors today.
Trade threats from Washington have become a familiar pattern, but this particular confrontation carries weight beyond typical tariff disputes. Spain represents a significant European economy and a longtime NATO ally. When the White House threatens to cut off trade with a European partner over military base access, we’re watching the convergence of defense policy, trade relations, and alliance politics. This combination creates uncertainty that markets hate.
The immediate economic concern centers on supply chain disruptions. Spain serves as a major gateway for U.S. goods entering Europe and hosts important manufacturing operations for American companies. Any actual trade disruption would ripple through aerospace, automotive, and agricultural sectors. European stocks with exposure to transatlantic trade face headwinds from this kind of political volatility, even if the threats never materialize into actual policy.
Defense contractors represent an interesting angle here. Increased tensions between the U.S. and European allies typically push European nations toward greater defense spending independence. Germany, France, and other EU members have already been moving toward building their own defense industrial base. Spain’s confrontation with Washington could accelerate that trend, benefiting European defense manufacturers while potentially pressuring American contractors who rely on NATO contracts.
The broader European market context matters too. The euro has been sensitive to transatlantic political friction, and currency volatility creates real costs for multinational corporations and international investors. When political leaders threaten trade cutoffs, currency markets react before any actual policy changes occur. European equities denominated in euros become less attractive to American investors when exchange rate uncertainty increases.
The key monitoring points are straightforward. First, watch for any actual policy implementation rather than just rhetoric. Presidential threats and actual trade policy represent very different risk levels. Second, pay attention to how other European leaders respond. If Spain’s position gains support from major EU economies, the situation escalates from a bilateral dispute to a broader Atlantic rift.
Third, track defense spending announcements from European governments. Any acceleration of European defense independence programs would shift capital flows and create new investment opportunities. Fourth, monitor the dollar-euro exchange rate for signs of sustained pressure. Sharp currency moves often precede broader market volatility.
For individual investors, this situation argues for caution with concentrated European equity positions, particularly in sectors dependent on smooth U.S.-European trade relations. Companies with significant manufacturing footprints in Spain or heavy reliance on transatlantic supply chains face elevated risk. The aerospace sector deserves particular scrutiny given Spain’s role in European aerospace manufacturing and the sector’s sensitivity to trade policy.
Defensive positioning makes sense when geopolitical tensions escalate. Consider increasing exposure to sectors that benefit from international friction rather than suffer from it. Energy companies often perform well during Middle East tensions. Defense contractors with diversified geographic revenue streams provide some insulation. Technology companies with minimal physical supply chain exposure to Europe offer another option.
Currency hedging deserves consideration for investors with meaningful European equity exposure. The cost of hedging has increased with volatility, but protecting against sharp euro weakness could preserve capital if the situation deteriorates. Alternatively, reducing European equity allocation in favor of domestic U.S. positions eliminates the currency risk entirely.
The situation also highlights the value of geographic diversification beyond Europe and the U.S. Asian markets, particularly those less entangled in Western alliance politics, may offer better risk-adjusted returns when Atlantic relationships face strain. Emerging markets with their own regional dynamics provide some insulation from U.S.-European political friction.
This dispute probably gets resolved through diplomatic channels rather than actual trade cutoffs. Economic interdependence between the U.S. and Spain runs deep enough that severing trade would hurt both sides. But the threat itself creates uncertainty, and uncertainty creates volatility. Smart investors position for volatility while avoiding panic. That means maintaining diversification, keeping some cash for opportunities, and staying alert to how the situation develops rather than making dramatic portfolio shifts based on political headlines alone.
Nothing in this article should be considered personalized financial advice. Always conduct your own due diligence when investing. We urge you to read our full disclaimer by clicking on the terms of use link below.
Get the latest financial news and market insights delivered to your inbox daily.Subscribe
RJ Hamster
Heavy on Suns is your mobile-friendly hub for Phoenix Suns news alerts, roster updates, starting lineup, injury report, players’ stats and game odds.
— Read on heavy.com/sports/nba/phoenix-suns/
RJ Hamster
1st Trading Group – 1st Trading Group – Investing and Stock News
— Read on 1sttradinggroup.com/
RJ Hamster
RJ Hamster
I tried out Elon Musk’s new AI tech — it floored me (From InvestorPlace)
Written by Chris Markoch on March 1, 2026
The Wendy’s Co. (NASDAQ: WEN)delivered a double beat when it reported Q4 2025 earnings on Feb. 13. However, shareholders lost their appetite for WEN stock, which pushed it to its 52-week low at $6.73. Recent headlines have helped the stock make a rally, but the stock is still down nearly 51% in the last 12 months, and over 61% over the last five years.
This is a case where big numbers worked against the company. In this case, Wendy’s posted its worst same-store sales numbers in 20 years. That’s a hard thing for shareholders to overlook, and they didn’t.
But has the stock become so bad, it’s good? As has been the case with many retail stocks, sometimes beauty is in the eye of the beholder. One person who seems to think so is the hedge fund billionaire, Nelson Peltz. Peltz has been a major shareholder for over two decades and has been evaluating ways to enhance shareholder value. An SEC filing revealed that one option could be a takeover of the fast-food chain.
However, Wendy’s is already undergoing a transformation (Project Fresh). Plus, the company is committed to closing between 5% and 6% of its locations in 2026. Wendy’s has also taken steps to make its value menu (i.e, the Biggie Bag) more competitive.
So, it’s unclear what value Peltz will try to unlock. One thing may be to land on a permanent chief executive officer (CEO). The company is currently being steered by interim CEO Ken Cook. Nevertheless, it’s better to evaluate the stock on its current merits.
President Trump is about to rewrite the rules of the stock market.
2025 showed just how much influence he has…
Liberation Day triggered the fastest 10% drawdown in recent memory — wiping over $2 trillion off the markets in a single day.
Then he paused tariffs for 90 days — and the S&P 500 gained $4 trillion in value.
His AI initiatives sent Palantir soaring over 140%.
But Larry Benedict says all of that was just the warm-up for what Trump is planning to do next.Larry is calling it “Project 2026.”
The fact that Wendy’s beat on the top and bottom lines was legitimately better-than-expected and not just better-than-feared. Still, it’s hard to ignore such a steep drop in same-store sales.
The challenge is in interpretation. To say investors are looking through a glass darkly is an understatement. It’s not hard to find positive outlooks for the economy. But that may depend on which leg of the “K-shaped” economy is being discussed.
It’s clear that lower-income consumers are clearly under pressure. If the debate is over which $5 value meal offers the most “value,” then the problem may lie with the consumer more than with the company.
Now add in GLP-1 concerns, and it’s not hard to make a case that Wendy’s may be playing their hand as well as can be expected. In 2021, this was a $20 stock. But as the saying goes, that was then.
Wendy’s is forecasting relatively flat global sales growth with adjusted earnings per share (EPS) falling to a range between 56 cents and 60 cents. That’s a 32% decline if the company hits the high end of that forecast.
The company is cutting back on its capital expenditures by approximately $10 million to $20 million. It’s also forecasting its free cash flow (FCF) to drop to $190 million from $205 million.
But those numbers have a “more of the same” bias in them. That’s not a bad strategy because 2026 is shaping up to be a year in which a range of outcomes for that lower leg of the K are possible.
One bright spot for WEN stock remains its dividend.
The payout got slashed nearly in half in 2025, but it still sits at 56 cents per share. With the company’s stock price as of this writing hovering around $7.70, that comes to a yield of 7.26%.
Of course, whenever investors see an attractive dividend yield after a report like the one Wendy’s delivered, there’s likely to be a question about sustainability. This is especially true due to the aforementioned drop in free cash flow.
That said, the dividend currently costs Wendy’s about $106 million. That’s sustainable even with the forecasted drop in FCF.
Ideally, investors would be more confident if the payout ratio were below 50% (it’s currently at 65.88%), but there’s no reason to believe the dividend is unsafe given the company’s own conservative projections.
Markets have been volatile lately, but dependable income opportunities still exist for investors who know where to look. We’re reviewing a small group of high-yield dividend stocks that continue to generate strong cash flow despite shifting conditions. Our latest guide outlines three companies operating in energy, consumer staples, and consumer finance, each producing billions in free cash flow and offering yields above typical market averages. These are established, cash-producing businesses built to reward shareholders through consistent payouts, not speculation. If steady income matters in today’s market, this breakdown is worth a closer look.Access the free dividend income guide and review all three stocks today
WEN stock has been in a relentless downtrend since March 2025, falling from roughly $16 to current levels near $7.73, consistently walking down the lower Bollinger Band for months. Price is now sitting right at the 20-day SMA (approx. $7.82), which has repeatedly acted as resistance throughout the decline rather than support.
Making matters worse, after the sharp February sell-off and subsequent bounce, the stock price has mean-reverted to the middle band. This means the oversold condition from that pullback has already been relieved. That suggests the recovery was corrective rather than the start of a genuine reversal.
The moving average convergence/divergence (MACD) reinforces this view. While the MACD line briefly crossed above zero during the bounce, it’s rolling back over with the signal line still deeply negative (-0.1239). Resistance at the upper Bollinger Band (approx. $8.41) remains a significant hurdle, and without reclaiming that level convincingly, the path of least resistance continues to point downward.
Recommended Stories
Did you like this article?
Thank you for subscribing to TickerReport, where we work around-the-clock
to bring you the latest market-moving news.
Contact Us | Unsubscribe
Copyright 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 N Reid Pl. #620, Sioux Falls, SD 57103-7078. United States of America..
RJ Hamster
*Sponsored
Paul Prescott Just Put Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) On Tomorrow’s Watchlist—Thursday, March 5, 2026
Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
My Full Coverage On (CTXR) Will Start Early
Pull Up (CTXR) Before Tomorrow Morning…
March 4, 2026
Thursday’s Watchlist | See Why (CTXR)Just Hit Tomorrow’s Radar
Dear Reader,
A major shift is unfolding across biotech right now—and it’s changing how quickly a little-known company can move from development headlines to real commercial traction.
For years, the biggest moments in this space centered on trial readouts and FDA decisions.
But the story changes when a company proves it can do what most never reach: launch, distribute, and start generating real revenue.
That transition is rare, difficult, and often the moment broader market attention begins to build.
And today, one name just checked an important box that the Street tends to watch closely.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) recently reached a significant inflection point, reporting its first-ever product revenue following a major year-end launch.
With a pipeline aimed at large, high-value medical markets with significant unmet need—and a newly commercialized oncology asset—the company is positioning itself as an increasingly relevant player across critical care and oncology.
That’s why (CTXR) will be topping our watchlist tomorrow morning—Thursday, March 5, 2026.
But keep in mind, (CTXR) has less than 22M shares listed as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift.
Right now, (CTXR) is sitting below $1 and appears to be flying under the radar of many screens.
On the analyst front, Jason Kolbert of D. Boral Capital recently reiterated a $6 target, which suggests over 600% upside potential from the current $0.80 range.
His view reflects the value of the company’s oncology ownership and the potential impact of late-stage programs like Mino-Lok as they progress through remaining regulatory steps.
Now let’s take a closer look at what (CTXR) has in hand today—and why the combination of a newly launched asset and late-stage programs has caught our attention.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceuticalleader focused on developing and commercializing first-in-class critical care products.
The company’s strategy centers on high-value, proprietary formulations that address specific gaps in the current healthcare system, particularly in oncology and infectious diseases.
Currently, (CTXR) holds an approximately 74.8% ownership stake in its oncology subsidiary, which recently reached a pivotal commercial turning point.
The company’s focus is on “first-in-class” solutions, meaning they are not merely seeking to improve upon existing treatments but are aiming to provide the first FDA-approved prescription options for specific indications.
This distinctive approach allows (CTXR)to operate in markets with limited competition and high barriers to entry.
In December 2025, the company’s oncology subsidiary officially launchedLYMPHIR, a targeted immunotherapy designed for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
This launch represents the culmination of years of development and marks the transition of (CTXR) from a pure research entity into a revenue-generating company.
Beyond oncology, the company maintains a robust pipeline featuring Mino-Lok, a solution for catheter-related infections, and Halo-Lido, a topical treatment for hemorrhoids.
By focusing on therapeutic areas with limited competition, (CTXR) aims to capture significant shares of niche but lucrative medical markets.
The leadership team, bolstered by decades of experience in the pharmaceutical space, has systematically navigated the regulatory landscape to bring these products to the doorstep of commercialization.
The primary driver for (CTXR) at the start of 2026 is the commercial rollout of LYMPHIR. In February 2026, the company announced it had generated $3.9M in revenue from initial sales in December 2025 alone.
This rapid start suggests a strong initial uptake in the medical community for this CTCL treatment.
The oncology subsidiary estimates the addressable U.S. market for LYMPHIR to be over $400M, providing a substantial runway for growth as the product gains wider adoption among oncologists.
This revenue stream is critical as it provides a proof-of-concept for the company’s ability to market and sell complex biologics effectively.
Market Landscape And Industry Trends
The oncology landscape continues to shift toward targeted immunotherapies that aim to deliver strong efficacy with fewer side effects than traditional chemotherapy.
LYMPHIR aligns with this trend as a targeted approach in a treatment-experienced patient population.
At the same time, critical care—particularly hospital-acquired infections—remains an area where better solutions are still needed.
(CTXR) is addressing this through Mino-Lok, which is designed to salvage central venous catheters in patients with bloodstream infections. Today’s standard of care often requires painful and costly catheter removal and replacement.
By offering a catheter-salvage approach, Mino-Lok is positioned within a market the company cites as exceeding $2B globally, including over $1B in the U.S.
The economic incentive for hospitals to adopt Mino-Lok is clear: reducing the number of surgical procedures and the length of hospital stays. This alignment of patient outcomes and hospital economics is a cornerstone of the (CTXR) business model.
As healthcare systems worldwide look to optimize costs while improving care, Mino-Lok stands out as a high-value asset that could redefine the standard of care for millions of patients annually.
(CTXR) has secured a formidable position by targeting “orphan” indications and niche medical needs that larger pharmaceutical companies often overlook.
This strategy has led to the successful completion of a pivotal Phase 3 trial for Mino-Lok, which met both its primary and secondary endpoints.
Meeting these endpoints in a Phase 3 trial is a significant de-risking event for the company, as it demonstrates clinical efficacy and safety at a scale required for FDA approval.
In addition to its clinical successes, (CTXR) has demonstrated savvy financial management. In February 2026, the company secured $3.8M in non-dilutive capital through the New Jersey Economic Development Program.
This program allows technology and life sciences companies to sell their net operating losses and research and development tax credits for cash.
By utilizing this program, (CTXR) has been able to fund its continued execution without diluting existing shareholders, a move that reflects a commitment to long-term value creation.
While LYMPHIR and Mino-Lok are the current headliners, the potential of Halo-Lido should not be underestimated.
Targeting the symptomatic relief of hemorrhoids, this formulation addresses a massive patient population.
Over 10M people in the U.S. report symptoms, yet there is a glaring absence of FDA-approved prescription products that combine a corticosteroid and an anesthetic.
(CTXR) completed a Phase 2b trial for this program in 2023 and is currently working with the FDA to outline the next steps for a Phase 3 study.
The company’s roadmap is clear:
This three-pronged approach ensures that (CTXR) has multiple paths to significant valuation growth over the next 12 to 24 months.
Each program targets a different segment of the healthcare market, providing a balanced portfolio that mitigates the risks inherent in any single drug development program.
Financially, (CTXR) is in a transition phase, moving from heavy R&D spending to a model supported by product sales.
As of its fiscal year 2025 report, the company has focused on maintaining a lean operational structure while directing resources toward its most promising assets.
The leadership team is a key component of the company’s strength. Leonard Mazur, Chairman and CEO, is a prominent figure in the pharmaceutical industry with a track record of building successful companies and executing high-value exits. Myron Holubiak, Vice Chairman, previously served as President of Roche Laboratories, bringing top-tier institutional knowledge to this agile organization.
1. Small Float: fewer than 22M shareslisted as available to the public means (CTXR) can react quickly when demand begins to build.
2. Analyst Target: coverage from D. Boral Capital includes a reiterated $6 target, placing (CTXR) at levels that suggest more than 600% upside potential from its recent $0.80 range.
3. Commercial Launch: a major milestone arrived when LYMPHIR became commercially available in December 2025, marking the shift of (CTXR) into a revenue-generating company.
4. First Revenue: early commercialization progress has begun as (CTXR) reported $3.9M from initial LYMPHIR sales following its December 2025 launch.
5. Phase 3 Success: strong clinical data was established after the Mino-Lok program met both primary and secondary endpoints in a pivotal Phase 3 trial tied to catheter-related infections.
6. Large Markets: major healthcare demand areas are being addressed as (CTXR) pursues indications tied to a $400M CTCL market and a catheter infection market exceeding $2B globally.
7. Pipeline Depth: multiple late-stage programs remain in motion with LYMPHIR commercialization underway while (CTXR) advances Mino-Lok regulatory steps and Halo-Lido Phase 3 planning.
Pull Up (CTXR) Before Tomorrow Morning…
Taken together, the pieces surrounding (CTXR) create a story worth paying attention to. The company has already crossed an important threshold with the commercial launch of LYMPHIR and the first reported revenue tied to that rollout.
At the same time, fewer than 22M shares listed as available to the public means activity can become more reactive when attention increases.
Add in a reiterated $6 analyst targetfrom D. Boral Capital, recent Phase 3 success for the Mino-Lok program, and additional late-stage work underway with Halo-Lido, and it becomes clear why (CTXR) could start to appear on more screens.
Beyond those developments, the company is working in areas tied to meaningful healthcare demand—from a CTCL market estimated around $400Mto catheter-related infection treatment markets that exceed $2B worldwide.
With commercialization now underway and several programs advancing toward their next milestones, the coming months could prove to be an important period for (CTXR).
We will have all eyes on (CTXR)tomorrow morning.
Take a look at (CTXR) before you call it a night.
Also, keep a lookout for my morning update.
Have a good night.
Sincerely,
Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 03/04/2026 and ending on 03/05/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC eight thousand seven hundred fifty USD (“Funds”). To date, including under the previously described agreement, 147 Media LLC has been paid thirty three thousand seven hundred fifty USD (“Funds”). These Funds were part of the fifty five thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither 147 Media LLC, TD Media LLC and their member own shares of (CTXR:US).
Please see important disclosure information here: https://street-ideas.com/disclosure/ctxr-C7PxT/#detailsStreet Ideas6586 W Atlantic AveUnit #2086Delray Beach, FL 33446UnsubscribeUpdate Profile | Constant Contact Data NoticeSent by paul@street-ideas.com
RJ Hamster
Deadline at Hand for Zacks’ Greatest Investment Value
Zacks Member,
This is a final reminder to take advantage of an exclusive opportunity before the deadline at midnight tonight.
Until then, you can claim our highest level of membership at a fraction of its value —the lowest cost available.
As I reported earlier today, this is flat-out the best value we offer at Zacks in terms of how much you get for how little it costs.
Time’s running short, so let me sum up the key points that make this arrangement so special:•A deep discount on your one-time membership payment. The temporary savings are unbelievable and there will never be extra fees or add-on charges.•Permanent access to the real-time buys, sells, and market commentaryof all Zacks’ private portfolio services, which closed 286 double- and triple-digit winners in 2025 alone. Recent gains have reached as high as +198.4%, +499.3%, +627.5%, and even +2,027.7%.¹ While not every pick will be a winner, just one could more than cover the cost of your membership.•Money-Back Satisfaction Guarantee.If the service has not exceeded your expectations, you can cancel up to 90 days after your one-time payment and receive a full refund for it.•Unprecedented Money-Back 3-year Performance Guarantee. If we don’t help you beat the market, we’ll refund your subscription.
Click the button below for your chance to make money and build wealth today and for many years to come.
I urge you not to miss this brief window of opportunity. The deadline is Wednesday, March 04 – midnight tonight.▶ See Stocks Now
All the Best,
Kevin Matras, EVP
¹The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research’s newsletter editors and may represent the partial close of a position. Access grants you a comprehensive list of all open and closed trades.
This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks “Terms of Service”. https://www.zacks.com/terms_of_service
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or U.S. investment adviser or investment bank.
The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through February 2, 2026. The performance is the equal weighted performance of a hypothetical portfolio consisting of stocks with a Zacks Rank of #1 that was rebalanced monthly from January 1988 through December 2013 and weekly from 12/31/13 through Monday’s open on February 2, 2026. For each stock with a Zacks Rank #1 at the beginning of the month, the total return during the month was calculated as the % change in the price of the stock from the closing price of the prior month to the closing price of the current month plus any dividends received during the month. The monthly individual stock returns were then averaged to determine the portfolio return for the month. For each stock with a Zacks Rank #1 at the beginning of the week, the total return during the week was calculated as the % change in the price of the stock from the opening price for the week to the opening price of the next week plus any dividends received during the week. The weekly individual stock returns were then averaged to determine the portfolio return for the week. If no month-end price or week end open price was available for a stock, it was not included in the portfolio return for the month or the week. The monthly and weekly returns were compounded to arrive at the annual returns. The annualized return is the annual return that, had it been achieved in each year or portion of a year, would have compounded to create the total return over the full time period. These returns are based on the list of Zacks Rank #1 Stocks that was available to clients of Zacks as of the beginning of the month, when returns were calculated monthly, or as of the beginning of the week when returns were calculated weekly. These returns are higher than the returns an investor could achieve investing real money in a portfolio of Zacks Rank #1 stocks because the returns of the hypothetical Zacks Rank #1 portfolio exclude a number of costs, including commissions incurred for trading, the average bid ask spread, the price impact of the trading and, prior to 2013, in those months when the end of the month fell on Friday, Saturday or Sunday, the overnight return from the month end close to the open on the next trading day. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance_disclosure for information about the performance numbers displayed above.
Zacks Emails
If you would prefer to not receive future profit-producing emails from Zacks.com the primary purpose of which is the commercial advertisement or promotion of a commercial product or service, then please click here and confirm your request. If you have trouble with the unsubscribe link, please email support@zacks.com.
Zacks Investment Research
101 N Wacker Drive, Floor 15
Chicago, IL 60606
RJ Hamster
Serious question, folks…
— Read on istandforfreedom.com/iran-missile-nato-turkey/